Reports
From White Space to Benchmark Space
What the next wave of HS therapies must prove. Why IRAK4, IL-1-axis therapies, and oral immunology assets now need proof of position, not just proof of biology.
HS Therapy Market Intelligence
Immunology
Hidradenitis Suppurativa
Target Prioritisation
The HS market has moved. A visible benchmark has been set — and the rules for every new entrant have changed. IRAK4, IL-1-axis, and oral immunology assets are now converging on the same patient population at the same time, creating a pressure point that most teams haven't fully priced in. Biological plausibility is no longer enough to justify a program. The evidence bar has shifted. The question is no longer whether your mechanism could work, it's whether your asset can prove where it fits, and why clinicians would choose it over what already exists.
So which mechanisms clear the bar, and which are running out of time to prove it?
CONTENTS
01
Executive Summary
02
Why this matters now
03
HS has entered benchmark space
04
Disease burden & patient journey
05
The treatment benchmark has moved
06
The next wave
07
IRAK4 as the test case
08
Modality is strategy
09
The evidence gap
10
Clinician reality check
11
Proof of Position
12
What the next HS asset must show
13
Biomarker strategy
14
Strategic implications
15
About Techspert & methodology
16
References